Author:
Shimamoto Yuki,Takahashi Naoki,Katoh Nagaaki,Matsui Yuki,Mochizuki Yusuke,Ito Masanori,Yazaki Masahide,Kametani Fuyuki,Kasuno Kenji,Sekijima Yoshiki,Naiki Hironobu,Iwano Masayuki
Abstract
Abstract
Background
Light and heavy chain deposition disease (LHCDD) is a rare condition characterised by the deposition of immunoglobulin components in the kidneys. Similarly, Amyloidosis is also caused by the deposition of light chain and/or heavy chain components of immunoglobulins which are folded into amyloid fibrils characterised by Congophilic deposits that exhibit apple-green birefringence under polarised light. Only a handful of reports describing LHCDD with amyloid fibril deposition have been previously published, however, none have characterized the composition of the deposited immunoglobulin components via mass spectrometry.
Case presentation
We report a case of a 79-year-old Japanese woman with nephrotic syndrome. Bone marrow aspiration revealed a slight proliferation of plasma cells (under 10%). Immunofluorescence assessment of renal biopsy showed amyloid-like deposits in the glomerulus that were positive for IgA and kappa. Further, the Congo red staining of the deposits was faintly positive, and only a slight birefringence was detected. Electron microscopy confirmed fine fibrillar structures and non-amyloid deposits. Finally, mass spectrometry revealed that the deposits were composed of abundant amounts of light chain with small amounts of heavy chain. Therefore, the patient was diagnosed with LHCDD and focal amyloid deposition. Chemotherapy was subsequently initiated, which resulted in haematological and renal response. Under polarised light, faint birefringence with Congo red staining and periodic acid-methenamine silver positivity indicated that the deposits were mostly non-amyloid fibrils with a small component of amyloid fibrils. Generally, the diagnosis of heavy- and light-chain amyloidosis is defined by greater heavy chain deposition compared to the light chain. However, in our case, contrary to the definition, the light-chain deposition was far greater than that of the heavy-chain.
Conclusions
This is the first case of LHCDD with focal amyloid deposition diagnosed by analysing the glomerular deposits by mass spectrometry.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Preud’Homme JL, Morel-Maroger L, Brouet JC, Mihaesco E, Mery JP, Seligmann M. Synthesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol. 1980;42:545–53.
2. Sakakima M, Fujigaki Y, Tsuji T, Fukasawa H, Miyaji T, Naito K, et al. High dose chemotherapy and stem cell support in a patient of light- and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med. 2005;44:970–4.
3. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13:1438–45.
4. Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clin J Am Soc Nephrol. 2020;15:404–11.
5. Manabe S, Iwasaki C, Hatano M, Kametani F, Yazaki M, Nitta K, et al. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; A case mimicking AHL amyloidosis. BMC Nephrol. 2018;19:1–6.